Arkbioa Is A Global Biotech Company Focused On Developing Innovative Therapies For Respiratoryinfectiousand Pediatric Diseasesfounded In 2014It Has Built Core Technology Platforms And A Differentiated R&D Pipeline Through In House Research And Collaborationskey Assets Includea Ziresovirthe First Direct Acting Rsv Antiviral With Positive Pivotal Phase Iii Results Globallyanda Ak0901An Fda Approved Pediatric Adhd Therapy With Arkbio S Commercialization Rights In Greater China A Arkbio Has Established Strategic Partnerships With Several Multinational Pharmaceutical Companies And Academic Institutesincluding Rochegenentech A The Scripps Research Institutethe Institute Of Microbiologychinese Academy Of Sciencesdomestic And International Biotechnology Companiesas Well As Venture Investment Institutions A
